Anticancer agent 76

Anticancer agent 76 (Compound CT2-3) is an anticancer agent. Anticancer agent 76 significantly inhibits the proliferation of human NSCLC cells, induces cell cycle arrest, causes ROS generation and induces cell apoptosis[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Topoisomerase

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> ROS

Signaling Pathways >> Apoptosis >> c-Myc

Anticancer agent 76 (Compound CT2-3) (0-80 μM, 24 h) inhibits the proliferation of human NSCLC cells[1]. Anticancer agent 76 (40 μM, 24 h) arrests cell cycle at G1 phase, induces apoptosis and ROS, suppresses the expression of c-Myc and topoisomerases in NSCLC cells [1]. Cell Proliferation Assay[1] Cell Line: A549 and H460 Concentration: 0, 10, 20, 40, 60 and 80 μM Incubation Time: 24 h Result: Inhibited the proliferation with IC50 values of 41.63 μM and 38.03 μM against A549 and H460 cells, respectively. Cell Cycle Analysis[1] Cell Line: H460 Concentration: 40 μM Incubation Time: 24 h Result: Resulted in increasing cell populations at the G1 phase, down-regulated CDK4, CDK6 and cyclin D1. Apoptosis Analysis[1] Cell Line: A549 and H460 Concentration: 20 μM and 40 μM Incubation Time: 24 h Result: Induced apoptosis. Western Blot Analysis[1] Cell Line: H460 cell Concentration: 40 μM Incubation Time: 24 h Result: Down-regulated mRNA of TOP2B, TOP3B and c-Myc.

[1]. Chen J, et al. CT2-3, a novel magnolol analogue suppresses NSCLC cells through triggering cell cycle arrest and apoptosis. Bioorg Med Chem. 2020 Mar 15;28(6):115352.